CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02890329
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:21.023335+00:00
Published At: 2025-01-07T00:00:00+00:00
Record Updated At: 2025-09-09
Results Posted At: 2025-01-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Previously Treated Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-09"
protocolSection.identificationModule.nctId: "NCT02890329"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-01-07"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.